Pfizer's COVID-19 Vaccine Brings Gaps In Efficacy And Safety Data To US FDA Panel
Executive Summary
Agency details a host of unknowns regarding the benefits and risks of the first COVID-19 vaccine to reach the advisory committee stage, including uncertainties about duration of protection, effectiveness against transmission and vaccine-enhanced disease.
You may also be interested in...
COVID-19 Vaccine Race: With Moderna EUA, US FDA Finally Gets Some Bragging Rights
US FDA’s global first for Moderna’s vaccine gets a small mention as agency looks to pharmacovigilance, follow-up studies for both coronavirus inoculations that have now been authorized. Moderna's 18 December EUA comes after an even faster review than for Pfizer/BioNTech's vaccine.
Severe and Asymptomatic Data Could Give Moderna’s COVID-19 Vaccine Slight Edge Over Pfizer’s
Moderna’s COVID-19 vaccine looks better than Pfizer/BioNTech’s at preventing severe disease and like it may offer some benefit in preventing asymptomatic infections, but these advantages may be short-lived and hard to capitalize on due to supply limitations.
Severe and Asymptomatic Data Could Give Moderna’s COVID-19 Vaccine Slight Edge Over Pfizer’s
Moderna’s COVID-19 vaccine looks better than Pfizer/BioNTech’s at preventing severe disease and like it may offer some benefit in preventing asymptomatic infections, but these advantages may be short-lived and hard to capitalize on due to supply limitations.